ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: L12

Immunological Phenotyping of a Cohort of American Travelers with Chikungunya Viral Arthritis

Jonathan Miner1, Han Xian Aw yeang1, Julie Fox1, Samantha Taffner1, Alfred Kim2, Michael Diamond1, Deborah Lenschow3 and Wayne Yokoyama1,4, 1Department of Medicine, Washington University in Saint Louis School of Medicine, Saint Louis, MO, 2Medicine, Washington University in Saint Louis School of Medicine, Saint Louis, MO, 3Washington University in Saint Louis School of Medicine, Saint Louis, MO, 4Howard Hughes Medical Institute, Saint Louis, MO

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: CyTOF, rheumatoid arthritis (RA) and viruses

  • Tweet
  • Email
  • Print
Session Information

Title: ACR Late-breaking Abstract Poster Presentations

Session Type: Late-Breaking Abstracts

Background/Purpose: Chikungunya virus (CHIKV) is a rapidly emerging arthritogenic mosquito-borne alphavirus that spread to the United States in 2014.  After an initial period of acute inflammatory arthritis, fever, and rash, patients with CHIKV infection often develop inflammatory arthritis that can persist for months to years.  Prior investigations were primarily focused on the infectious nature of the disease and patients from the Eastern Hemisphere.  Here, we describe the rheumatologic and immunologic features of a cohort of 10 American travelers who were almost simultaneously infected with CHIKV in Haiti, and compared them to newly diagnosed, untreated rheumatoid arthritis (RA) patients.

Methods: CHIKV infection was confirmed by the presence of anti-CHIKV IgG antibodies detected by enzyme-linked immunosorbant assay (ELISA). Features of disease were assessed by history, physical examination, and laboratory studies.  Peripheral blood mononuclear cells from RA and CHIKV-infected patients were phenotyped by mass spectometry (CyTOF).

Results: Eight of 10 CHIKV-infected individuals developed symmetric polyarthritis that persisted for a minimum of 6 weeks after the initial infection. Once the acute infectious symptoms resolved, the clinical features of CHIKV-related arthritis were indistinguishable from seronegative RA. CyTOF analysis of peripheral blood mononuclear cells suggested that both RA and CHIKV-infected patients had higher percentages of activated and effector CD4+ and CD8+ T-cells than healthy controls.  Spanning tree progression of density normalized events (SPADE) analysis of activation marker expression revealed a trend toward higher L-selectin expression in CD4+ T cells from RA patients compared to healthy controls and patients with CHIKV-associated arthritis.

Conclusion: Patients with persistent CHIKV arthritis exhibit T cell phenotypes similar to patients with untreated, active RA.  Given that CHIKV-related arthritis clinically mimics seronegative RA, there is a need for rheumatologists to consider CHIKV infection in the differential diagnosis of symmetric polyarthritis, especially since immunosuppression has the potential to exacerbate a virus-induced arthritic disease.  Rheumatologists should take a travel history and consider possible CHIKV exposure in patients with new-onset seronegative RA.


Disclosure:

J. Miner,
None;

H. X. Aw yeang,
None;

J. Fox,
None;

S. Taffner,
None;

A. Kim,

Pfizer Inc,

5,

Amgen,

5,

Janssen Pharmaceutica Product, L.P.,

5,

Kypha, Inc.,

2;

M. Diamond,
None;

D. Lenschow,
None;

W. Yokoyama,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immunological-phenotyping-of-a-cohort-of-american-travelers-with-chikungunya-viral-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology